Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have been assigned an average rating of “Moderate Buy” from the sixteen analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $199.5333.

PVLA has been the topic of a number of recent analyst reports. Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. HC Wainwright increased their price target on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Stephens reissued an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Chardan Capital restated a “buy” rating and set a $240.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock opened at $144.76 on Monday. Palvella Therapeutics has a 52 week low of $25.80 and a 52 week high of $161.38. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -34.71 and a beta of -0.20. The company’s 50-day moving average price is $122.66 and its two-hundred day moving average price is $113.73.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Research analysts expect that Palvella Therapeutics will post -5.26 earnings per share for the current fiscal year.

Insider Transactions at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the sale, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at $238,512.42. This represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 17.20% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Several institutional investors have recently made changes to their positions in the company. First Light Asset Management LLC grew its position in Palvella Therapeutics by 38.3% in the first quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock worth $122,251,000 after acquiring an additional 271,617 shares in the last quarter. Suvretta Capital Management LLC raised its holdings in shares of Palvella Therapeutics by 8.5% during the 4th quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock valued at $93,408,000 after purchasing an additional 70,000 shares in the last quarter. Jennison Associates LLC lifted its stake in shares of Palvella Therapeutics by 65.3% in the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock valued at $79,852,000 after purchasing an additional 253,128 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Palvella Therapeutics by 13.3% in the 4th quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock valued at $58,680,000 after purchasing an additional 65,960 shares during the last quarter. Finally, State Street Corp boosted its holdings in Palvella Therapeutics by 206.3% in the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after purchasing an additional 283,211 shares in the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.